Renee P. Tannenbaum

Dr. Tannenbaum is a strategic advisor for several biopharmaceutical and device companies and serves on the Cardiff Oncology, Inc. Board of Directors and as a Board Advisor to Aerami Therapeutics, Inc. She was previously Vice President of Global Partnering at Halozyme, Inc. and Head of Global Customer Excellence at AbbVie, where she was responsible for building commercial capabilities for the organization.

Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm and Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., where she was responsible for, among other things, revenue generation for Elan’s marketed products, preparing for the commercialization of the company's pipeline, and strengthening the company's overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG, where she led the Global Commercial Operations organization. She also spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions.